MESOBLAST LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.93 AUD | +1.64% |
|
+21.57% | +200.00% |
| Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
| Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
Valuation
| Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 730.3 | 1,886 | 1,282 | 396.4 | 923.5 | 1,061 | - | - |
| Enterprise Value (EV) 1 | 776.2 | 1,845 | 1,239 | 396.4 | 981.2 | 1,116 | 1,155 | 1,129 |
| P/E ratio | -2.73 x | -7.96 x | -4.42 x | -1.49 x | -3.33 x | -8.77 x | -8.64 x | -13.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 29.4 x | 42.3 x | 125 x | 26.7 x | 80 x | 92.2 x | 42.7 x | 4.49 x |
| EV / Revenue | 31.2 x | 41.4 x | 121 x | 26.7 x | 84.9 x | 96.9 x | 46.5 x | 4.77 x |
| EV / EBITDA | -6.7 x | -18.9 x | -10.7 x | -3.9 x | -11 x | -18.2 x | -14.5 x | -21.2 x |
| EV / FCF | -9 x | -22.8 x | -8.36 x | -4.14 x | -10 x | -14.3 x | -12.2 x | 42.1 x |
| FCF Yield | -11.1% | -4.39% | -12% | -24.2% | -9.97% | -7% | -8.22% | 2.38% |
| Price to Book | - | 3.7 x | - | - | 0.6 x | 1.22 x | 1.52 x | 2.03 x |
| Nbr of stocks (in thousands) | 495,126 | 580,450 | 647,399 | 649,912 | 813,662 | 1,141,241 | - | - |
| Reference price 2 | 1.475 | 3.250 | 1.980 | 0.6100 | 1.135 | 0.9300 | 0.9300 | 0.9300 |
| Announcement Date | 8/29/19 | 8/26/20 | 8/30/21 | 8/30/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.85 | 44.57 | 10.22 | 14.84 | 11.55 | 11.52 | 24.85 | 236.4 |
| EBITDA 1 | -115.8 | -97.4 | -115.9 | -101.6 | -89.11 | -61.46 | -79.39 | -53.31 |
| EBIT 1 | -119 | -102.5 | -121.9 | -107.9 | -95.44 | -76.46 | -89.55 | 73.92 |
| Operating Margin | -478.87% | -229.89% | -1,192.54% | -727.41% | -826.28% | -663.85% | -360.36% | 31.27% |
| Earnings before Tax (EBT) 1 | -146.7 | -120.8 | -136.5 | -133.1 | -126.4 | -103.4 | -121.6 | 53.95 |
| Net income 1 | -133.4 | -107.8 | -135.4 | -132.7 | -126.1 | -103.3 | -121.2 | 31.14 |
| Net margin | -537.01% | -241.93% | -1,325.25% | -894.33% | -1,091.71% | -897.02% | -487.68% | 13.17% |
| EPS 2 | -0.5396 | -0.4081 | -0.4476 | -0.4091 | -0.3412 | -0.1061 | -0.1077 | -0.0690 |
| Free Cash Flow 1 | -86.28 | -80.93 | -148.3 | -95.8 | -97.83 | -78.19 | -94.96 | 26.81 |
| FCF margin | -347.26% | -181.56% | -1,450.88% | -645.57% | -846.99% | -678.9% | -382.15% | 11.34% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 86.11% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/29/19 | 8/26/20 | 8/30/21 | 8/30/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.26 | 18 | 4.596 | 5.359 | 4.978 | 3.342 | - | 2.806 | 3.234 | 6.156 | 2.267 | 3.173 | 5.407 | 2.98 | 3.294 | 5.951 | 5.219 | - | 6.612 | 3.998 | - | 5.843 | 5.612 | - | 6.228 |
| EBITDA | -39.9 | -61.15 | -58.17 | -54.44 | - | - | -52.58 | - | - | -47.1 | - | - | -42.56 | - | - | -45.04 | -30.62 | - | - | - | - | - | - | - | - |
| EBIT | -42.52 | -63.85 | -60.83 | -57.55 | -26.38 | -28.95 | -55.66 | -24.32 | -24.94 | -50.28 | -18.77 | -27.32 | -45.82 | -21 | -26.96 | -49.36 | -34.39 | - | - | -42.29 | - | - | -44.13 | - | -45.9 |
| Operating Margin | -145.31% | -354.81% | -1,323.35% | -1,073.91% | -529.97% | -866.35% | - | -867.03% | -771.34% | -816.76% | -827.81% | -860.78% | -847.39% | -704.59% | -818.47% | -829.47% | -658.86% | - | - | -1,057.7% | - | - | -786.32% | - | -737.02% |
| Earnings before Tax (EBT) | - | -73.37 | -65.97 | -66.8 | -31.45 | -36.49 | - | -29.78 | -31.25 | -62.26 | -25.55 | -36.52 | -61.71 | -28.66 | -33.81 | -63.9 | -50.28 | - | - | -57.66 | - | - | -59.7 | - | -64.2 |
| Net income | -45.87 | -66.17 | -65.12 | -66.57 | -31.37 | -36.38 | - | -29.72 | -31.17 | -62.12 | -25.47 | -36.41 | -61.52 | -28.59 | -33.75 | -62.39 | -50.13 | - | - | -57.66 | - | - | -59.7 | - | -64.2 |
| Net margin | -156.77% | -367.69% | -1,416.69% | -1,242.33% | -630.08% | -1,088.75% | - | -1,059.27% | -963.84% | -1,009.13% | -1,123.35% | -1,147.42% | -1,137.79% | -959.26% | -1,024.73% | -1,048.36% | -960.42% | - | - | -1,442.32% | - | - | -1,063.72% | - | -1,030.83% |
| EPS | - | - | - | -0.2119 | -0.0967 | -0.1122 | - | - | - | -0.0959 | - | -0.0987 | -0.1719 | -0.0778 | -0.0859 | - | -0.0588 | - | - | -0.0620 | - | - | -0.0620 | - | -0.0620 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 8/26/20 | 2/26/21 | 8/30/21 | 11/23/21 | 2/24/22 | 2/24/22 | 6/1/22 | 8/30/22 | 8/30/22 | 11/22/22 | 2/27/23 | 2/27/23 | 5/25/23 | 8/30/23 | 8/30/23 | 2/28/24 | - | - | - | - | - | - | - | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 45.9 | - | - | - | 57.7 | 55.1 | 93.3 | 67.3 |
| Net Cash position 1 | - | 41.5 | 43 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.396 x | - | - | - | -0.647 x | -0.8957 x | -1.175 x | -1.262 x |
| Free Cash Flow 1 | -86.3 | -80.9 | -148 | -95.8 | -97.8 | -78.2 | -95 | 26.8 |
| ROE (net income / shareholders' equity) | -17.5% | -44.6% | -17.5% | - | -16.4% | -12.8% | -15.9% | -13.1% |
| ROA (Net income/ Total Assets) | -13.4% | -11.4% | -13.4% | - | -12.3% | -7.6% | -10.1% | -8.9% |
| Assets 1 | 998.9 | 943.7 | 1,013 | - | 1,025 | 1,359 | 1,200 | -349.9 |
| Book Value Per Share 2 | - | 0.8800 | - | - | 1.900 | 0.7700 | 0.6100 | 0.4600 |
| Cash Flow per Share | -0.3500 | -0.3000 | -0.4800 | - | - | - | - | - |
| Capex 1 | 0.41 | 2.9 | 2.25 | 0.23 | 0.41 | 3.58 | 4.09 | 8.67 |
| Capex / Sales | 1.67% | 6.51% | 22.06% | 1.54% | 3.52% | 31.08% | 16.45% | 3.67% |
| Announcement Date | 8/29/19 | 8/26/20 | 8/30/21 | 8/30/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.93
AUD
Average target price
1.1
AUD
Spread / Average Target
+18.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +200.00% | 692M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MSB Stock
- Financials Mesoblast Limited
